Loading data
RXONYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 5.74 bn USD | 4.55 bn USD | 3.93 bn USD | 4.8 bn USD | 4.69 bn USD |
| Selling, general and administrative expense | 832 m USD | 666 m USD | 591 m USD | 640 m USD | 539 m USD |
| Operating profit | -79 m USD | -56 m USD | 39 m USD | 123 m USD | 192 m USD |
| Profit before tax | -115 m USD | -304 m USD | 4 m USD | 119 m USD | 191 m USD |
| Income tax expense | -15 m USD | -14 m USD | 0 USD | 27 m USD | 41 m USD |
| Net income (reported basis) | -100 m USD | -290 m USD | 4 m USD | 92 m USD | 150 m USD |
| Net income attributable to common shareholders | -100 m USD | -290 m USD | 4 m USD | 92 m USD | 150 m USD |
| Basic earnings per share | -0.59 USD/share | -2.17 USD/share | 0.03 USD/share | 0.8 USD/share | 1.3 USD/share |
| Diluted earnings per share | -0.59 USD/share | -2.17 USD/share | 0.03 USD/share | 0.79 USD/share | 1.3 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.